$7.28
4.15% yesterday
NYSE, Jul 17, 10:10 pm CET
ISIN
US29089Q1058
Symbol
EBS
Sector
Industry

Emergent Biosolutions Inc Stock price

$7.28
+1.06 17.04% 1M
-2.60 26.32% 6M
-2.28 23.85% YTD
-4.74 39.43% 1Y
-22.88 75.86% 3Y
-96.92 93.01% 5Y
-25.25 77.62% 10Y
-3.77 34.12% 20Y
NYSE, Closing price Thu, Jul 17 2025
+0.29 4.15%
ISIN
US29089Q1058
Symbol
EBS
Sector
Industry

Key metrics

Basic
Market capitalization
$395.1m
Enterprise Value
$911.7m
Net debt
$516.6m
Cash
$149.1m
Shares outstanding
54.5m
Valuation (TTM | estimate)
P/E
negative | 10.1
P/S
0.4 | 0.5
EV/Sales
0.9 | 1.1
EV/FCF
9.7
P/B
0.7
Financial Health
Equity Ratio
34.7%
Return on Equity
-39.5%
ROCE
-5.3%
ROIC
-12.3%
Debt/Equity
1.2
Financials (TTM | estimate)
Revenue
$965.4m | $826.9m
EBITDA
$-4.9m | $174.9m
EBIT
$-70.1m | $75.1m
Net Income
$-131.6m | $39.4m
Free Cash Flow
$94.4m
Growth (TTM | estimate)
Revenue
-28.5% | -20.8%
EBITDA
99.1% | 1,166.7%
EBIT
88.6% | 192.2%
Net Income
82.5% | 120.7%
Free Cash Flow
169.5%
Margin (TTM | estimate)
Gross
35.3%
EBITDA
-0.5% | 21.2%
EBIT
-7.3%
Net
-13.6% | 4.8%
Free Cash Flow
9.8%
More
EPS
$-2.3
FCF per Share
$1.7
Short interest
14.9%
Employees
900
Rev per Employee
$1.2m
Show more

Is Emergent Biosolutions Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,004 stocks worldwide.

Emergent Biosolutions Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Emergent Biosolutions Inc forecast:

5x Buy
71%
1x Hold
14%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Emergent Biosolutions Inc forecast:

Buy
71%
Hold
14%
Sell
14%

Financial data from Emergent Biosolutions Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
965 965
28% 28%
100%
- Direct Costs 624 624
27% 27%
65%
341 341
32% 32%
35%
- Selling and Administrative Expenses 275 275
39% 39%
29%
- Research and Development Expense 71 71
44% 44%
7%
-4.90 -4.90
99% 99%
-1%
- Depreciation and Amortization 65 65
20% 20%
7%
EBIT (Operating Income) EBIT -70 -70
89% 89%
-7%
Net Profit -132 -132
82% 82%
-14%

In millions USD.

Don't miss a Thing! We will send you all news about Emergent Biosolutions Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Emergent Biosolutions Inc Stock News

Neutral
GlobeNewsWire
3 days ago
GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2025.
Neutral
GlobeNewsWire
10 days ago
GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exerci...
Neutral
GlobeNewsWire
16 days ago
Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis
More Emergent Biosolutions Inc News

Company Profile

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Joseph Papa
Employees 900
Founded 1998
Website emergentbiosolutions.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today